



## Clinical trial results:

### Effect of intravenous replenishment of iron in the preoperative management of anemia in patients with colon cancer: RIPAC-trial

#### Summary

EudraCT number	2018-004213-41
Trial protocol	BE
Global end of trial date	21 June 2021

#### Results information

Result version number	v1 (current)
This version publication date	08 August 2024
First version publication date	08 August 2024
Summary attachment (see zip file)	Final Study Report (2018-004213-41_Final_Study_Report.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	RIPAC
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Ghent University Hospital
Sponsor organisation address	C. Heymanslaan 10, Gent, Belgium, 9000
Public contact	Clinical Trial Unit, Health, Innovation and Research Institute, 32 93320500, hiruz.ctu@uzgent.be
Scientific contact	Clinical Trial Unit, Health, Innovation and Research Institute, 093321539 93320500, hiruz.ctu@uzgent.be

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 May 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	21 June 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

1. To investigate the increase in preoperative Hb after intravenous iron substitution compared with no iron substitution in patients with colon cancer and iron deficiency anemia who are eligible for surgery.

Protection of trial subjects:

See attachment Final Study Report

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 May 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 7
Worldwide total number of subjects	7
EEA total number of subjects	7

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	7
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

See attachment Final Study Report

### Pre-assignment

Screening details:

See attachment Final Study Report

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

See attachment Final Study Report

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Group with iron substitution
------------------	------------------------------

Arm description:

See attachment Final Study Report

Arm type	Active comparator
Investigational medicinal product name	Injectafer
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

See attachment Final Study Report

<b>Arm title</b>	Group without iron substitution
------------------	---------------------------------

Arm description:

See attachment Final Study Report

Arm type	No intervention
----------	-----------------

No investigational medicinal product assigned in this arm

Number of subjects in period 1	Group with iron substitution	Group without iron substitution
Started	2	5
Completed	1	4
Not completed	1	1
Adverse event, serious fatal	-	1
See attachment Final Study Report	1	-



## Baseline characteristics

## End points

### End points reporting groups

Reporting group title	Group with iron substitution
Reporting group description: See attachment Final Study Report	
Reporting group title	Group without iron substitution
Reporting group description: See attachment Final Study Report	

### Primary: Primary

End point title	Primary <sup>[1]</sup>
End point description: See attachment Final Study Report	
End point type	Primary
End point timeframe: See attachment Final Study Report	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: See attachment Final Study Report

End point values	Group with iron substitution	Group without iron substitution		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	5		
Units: Mean Hb increase				
number (not applicable)	2	5		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Secondary

End point title	Secondary
End point description: See attachment Final Study Report	
End point type	Secondary
End point timeframe: During the study	

<b>End point values</b>	Group with iron substitution	Group without iron substitution		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	5		
Units: Subjects				
number (not applicable)	2	5		

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

During the study

Adverse event reporting additional description:

See attachment Final Study Report

Assessment type	Systematic
-----------------	------------

### Dictionary used

---

Dictionary name	MedDRA
-----------------	--------

Dictionary version	0
--------------------	---

---

Frequency threshold for reporting non-serious adverse events: 1 %

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: See attachment Final Study Report



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported